Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 1,474 shares of Edwards Lifesciences stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $184.55, for a total value of $272,026.70. Following the completion of the transaction, the vice president now directly owns 20,250 shares of the company’s stock, valued at approximately $3,737,137.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of NYSE:EW opened at $183.93 on Monday. Edwards Lifesciences Corp has a fifty-two week low of $134.53 and a fifty-two week high of $197.86. The company has a quick ratio of 2.69, a current ratio of 3.66 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $38.35 billion, a price-to-earnings ratio of 38.32, a price-to-earnings-growth ratio of 2.35 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a return on equity of 31.16% and a net margin of 20.03%. The business had revenue of $993.00 million during the quarter, compared to analyst estimates of $989.87 million. During the same quarter in the previous year, the firm earned $1.22 EPS. Edwards Lifesciences’s revenue was up 11.0% on a year-over-year basis. Sell-side analysts forecast that Edwards Lifesciences Corp will post 5.29 earnings per share for the current year.

A number of large investors have recently modified their holdings of EW. Advisors Asset Management Inc. raised its holdings in shares of Edwards Lifesciences by 4.5% during the fourth quarter. Advisors Asset Management Inc. now owns 30,477 shares of the medical research company’s stock worth $4,668,000 after acquiring an additional 1,310 shares during the period. BB&T Securities LLC increased its stake in Edwards Lifesciences by 0.9% in the 4th quarter. BB&T Securities LLC now owns 8,179 shares of the medical research company’s stock valued at $1,252,000 after buying an additional 70 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in Edwards Lifesciences by 8.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 8,668 shares of the medical research company’s stock valued at $1,328,000 after buying an additional 652 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in Edwards Lifesciences by 10.8% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 18,150 shares of the medical research company’s stock valued at $2,780,000 after buying an additional 1,768 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in Edwards Lifesciences by 11.2% in the 4th quarter. Parallel Advisors LLC now owns 684 shares of the medical research company’s stock valued at $101,000 after buying an additional 69 shares during the last quarter. 81.99% of the stock is owned by institutional investors and hedge funds.

EW has been the subject of several recent analyst reports. Raymond James lowered their price target on Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating for the company in a research report on Wednesday, April 24th. Barclays lifted their price target on Edwards Lifesciences from $150.00 to $160.00 and gave the stock an “underweight” rating in a research report on Monday, March 25th. Morgan Stanley lifted their price target on Edwards Lifesciences from $180.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. UBS Group lifted their price target on Edwards Lifesciences from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 12th. Finally, Zacks Investment Research lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, May 16th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $186.52.

COPYRIGHT VIOLATION NOTICE: “Catherine M. Szyman Sells 1,474 Shares of Edwards Lifesciences Corp (NYSE:EW) Stock” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://theolympiareport.com/2019/06/17/catherine-m-szyman-sells-1474-shares-of-edwards-lifesciences-corp-nyseew-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: What is the formula for calculating total return?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.